TFAP2D

Across TCGA pan-cancer cohorts, TFAP2D Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TFAP2D data layer compared with 17 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TFAP2D Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TFAP2D expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

LIHC, UCEC, and DLBC are the cancer types where TFAP2D Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.095	0.548	<.001	27	view →
UCEC	DFS	Median	All	0.968	0.625	.013	14	view →
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
GBM	OS	Median	All	0.192	0.417	.010	6	view →
COAD	DFS	Median	II,III,IV	0.811	0.467	.043	2	view →
SARC	OS	Median	All	0.540	0.865	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TFAP2D–LIHC (DFS)

Open the LIHC breakdown →